Replies to post #2960 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

For sure at least some of the 2 billion would eat into Pfizer sales so 2025 paxlovid sales expectations should be revised up IMO
Ensitrelvir suffers from a lot of DDIs too so it wouldn’t have been such a big advance for high risk patients but it could have captured non high risk but now it probably is a stretch to thikk they make it to market at all although let’s see the 6 month long Covid data.
FDA is torpedoing next gen drugs with this strict 15 symptom primary. Japan approved using the most common handful of symptoms which I feel is a very reasonable endpoint (and more in line w flu which required 7 endpoints)
Perhaps the FDA will come around otherwise I’m not sure we are going to get anything other than paxlovid for Covid (and 235 IS an advance when it comes to DDIs but it doesn’t seem like anyone wants to touch it with the 15 symptom endpoint )
I still think this is bullish for enta by dint of a possible stake in paxlovid but the market doesn’t seem to agree